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Monitoring the COVID-19 epidemic in the context of 
widespread local transmission
Coronavirus disease 2019 (COVID-19) is a novel viral 
disease caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), which was first detected in 
Wuhan, China, in December, 2019.1 Given the fast spread, 
the severity of disease, the increasing number of cases 
outside China, and the number of affected countries, WHO 
declared the rapid spread of SARS-CoV-2 a pandemic on 
March 11, 2020.2 The availability of reliable surveillance 
platforms is crucial to monitor the COVID-19 epidemic in 
a timely manner and to respond with adequate control 
measures. Since the beginning of the outbreak, different 
countries have used different testing approaches and 
criteria, depending on their resources and capacity.
Most national and international public health agencies 
are publicly reporting epidemic curves, focus ing on 
laboratory-confirmed COVID-19 cases, as well as deaths by 
COVID-19. However, epidemic curves based on laboratory-
confirmed cases, regardless of whether they are presented 
on a logarithmic or linear scale, show detection of the 
disease in population groups defined by changing testing 
criteria and are not representative of the COVID-19 burden 
in the community in a specific region or country. The 
absolute number of cases provides a misleading picture of 
how the epidemic evolves and does not allow comparisons 
by country or by region within a country.
In almost all countries, COVID-19 testing capacity 
is low. When no or few cases of disease have been 
reported in a country, laboratory testing is restricted 
to travellers presenting with an acute respiratory 
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Figure: COVID-19 in Spain and Italy since first COVID-19 laboratory-confirmed case in each country
Absolute number of cases (A), cases per 100 000 population (reported incidence risk; (B), absolute number of deaths due to COVID-19 (C), mortality risk per 
100 000 population (D), absolute number of ICU admissions (E), and ICU admissions per 100 000 population (reported COVID-19 ICU admission risk; (F). Data 
sources are Ministries of Health of Spain and Italy; from March 26, 2020. COVID-19=coronavirus disease 2019. ICU=intensive care unit.
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widespread transmission. When contact tracing efforts 
are implemented, criteria for laboratory testing often 
include symptomatic contacts of confirmed cases or 
asymptomatic contacts during or after quarantine. 
After local transmission is established, some countries, 
such as South Korea, have chosen to test all individuals 
who have acute respiratory syndrome or who have 
had contact with a confirmed case.3 Because of limited 
testing capacity, other countries, such as Italy or Spain, 
have restricted laboratory testing to those seeking 
hospital care for severe COVID symptoms or to those 
prone to severe disease (the elderly and patients with 
comorbidities).4 Thus, curves based on confirmed 
cases in countries that have been changing the testing 
recommendations and are now using stringent testing 
criteria could provide a false impression of flattening 
(or unmask much steeper curves), which could lead to 
misinterpretation of the status of the epidemic.
By contrast, and as a basic epidemiological concept, 
comparisons of the number of COVID-19 cases by 
country or region should be adjusted by the size of 
the population at risk, using incidence risks (ie, new 
cases in a population at risk within a specified period 
of time, also called attack rates in the context of an 
epidemic). Similarly, mortality is better expressed as 
mortality risk (ie, number of deaths in a specific time 
interval divided by population size among which deaths 
occurred, commonly referred to as mortality rate; figure) 
and, if possible, should be stratified by age, given the 
differences in age-specific mortality rates for COVID-195,6 
and the differential age structure by country. When the 
epidemic is contained and all cases are identified and 
contacts traced, absolute number of cases would still 
be an acceptable indicator if testing criteria have not 
changed. However, the capacity of countries to detect 
imported cases varies but is generally poor, estimated to 
be around 38% at the global level.7
Thus, the crucial question is how to monitor disease 
burden when local transmission is widespread and a 
large proportion of the population has been quarantined 
or confined at home. We believe that the basic principle 
is to try to select an indicator that includes the 
numerator that is least affected by changing testing 
criteria and that is adjusted by population size. In regions 
with strong hospital admission or mortality surveillance 
systems, such an indicator could be the incidence risk 
of hospital admissions of laboratory-confirmed cases 
and COVID-19 mortality rates, which should provide 
a reliable picture of the epidemic, with the following 
assumptions: (1) most people with severe disease are 
admitted to hospital and are tested for SARS-CoV-2; 
(2) there is good access to health services; (3) public and 
private hospitals report cases and deaths on a regular 
(daily) basis; and (4) hospital admission criteria and 
patient management do not differ significantly by area. 
Nevertheless, the daily picture of the incidence of severe 
cases is an indicator of transmission several days before 
(incubation period plus time from symptom onset 
to hospital admission). Based on available evidence, 
this temporal lag is about 12 days, given a median 
incubation period of 5·1 days8 and a median time from 
symptom onset to hospital admission (assumed to be 
the onset of dyspnoea) of 7 days.9 In consequence, any 
intervention aimed at reducing the basic reproduction 
number, R0, would be expected to have an effect on 
the incidence of people admitted to hospital by about 
12 days later. Other reliable indicators to monitor the 
evolution of the epidemic would be the incidence 
of COVID-19 intensive care unit (ICU) admissions or 
COVID-19 mortality rates, although the temporal lag 
would be greater, reflecting changes in transmission 
that took place longer ago.
For COVID-19 surveillance purposes, the main objective 
is to detect changes in disease burden indicators that are 
more stable (in time or space). The main attribution of 
these indicators needs to be consistency, rather than valid-
ity. Despite some limitations (mainly different hos pital 
admission criteria or health system collapse), the incidence 
of people admitted to hospital for COVID-19 seems less 
biased yet still a pragmatic indicator, given that it can 
detect changes in transmission dynamics more quickly 
than the more lagged measures of (incidence of) ICU 
admissions and deaths (mortality rates). Unfortunately, 
many governments are not publicly providing numbers 
of daily hospital admissions and discharges. COVID-19 
mortality rate, in the long term, is probably the most 
reliable indicator in settings where cause of death is 
accurately ascertained.
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